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Abstract
Unlike opportunistic screening, population screening is accompanied by stringent
quality control measures and careful programme monitoring. Sufficient evidence for
benefit together with acceptable harms and costs to society are needed before
launching a programme. A screening programme is a complex process organized at
the population level involving multiple actors of the health care system that should
ideally be supervised by public health authorities and evaluated by an independent
and trustful body. Chronic kidney disease is defined by reduced glomerular filtration
rate and/or presence of kidney damage for at least three months. Chronic kidney
disease is divided into 5 stages with stages 1 to 3 being usually asymptomatic. Chronic
kidney disease affects one in ten adults worldwide and its prevalence sharply increases
with age. Kidney function is measured using serum creatinine-based, and/or
cystatin C-based, equations. Markers of renal function show high intra-individual
and inter-laboratory variabilities, highlighting the need for standardized procedures.
There is also large inter-individual variability in age-related kidney function decline.
Despite these limitations, chronic kidney disease, as currently defined, has been
consistently associated with high cardiovascular morbidity and mortality and high
risk of end-stage renal disease. Major modifiable risk factors for chronic kidney
disease are diabetes, hypertension, obesity and cardiovascular disease. Several
treatment options, ranging from antihypertensive and lipid-lowering treatments to
dietary measures, reduce all-cause mortality and/or end-stage renal disease in
patients with stages 1–3 chronic kidney disease. So far, no randomized controlled
trial comparing outcomes with and without population screening for stages 1–3
chronic kidney disease has been published. Population screening for stages 1–3
chronic kidney disease is currently not recommended because of insufficient
evidence for benefit. Given the current and future burden attributable to chronic
kidney disease, randomized controlled trials exploring benefits and harms of
population screening are clearly needed to prioritize resource allocations.
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Introduction
Chronic kidney disease (CKD) and its complications represent an enormous and in-
creasing public health burden worldwide [1]. More than one in ten adults suffers from
CKD in the general population [2], with a majority of people being in its early stages
(i.e. 1 to 3) [2]. In the general population, the prevalence of CKD sharply increases with
age [3]. CKD can be considered as a condition associated with premature ageing with
accelerated vascular disease [4]. The large number of people with CKD, or at high risk
of CKD (i.e. patients with hypertension, diabetes and/or CVD), implies that primary
care providers and specialists other than nephrologists frequently encounter patients
with CKD [5], a situation in which most CKD cases are diagnosed via opportunistic
kidney function screening or automated eGFR reporting.
The aim of this review is to discuss the rationale and currently available evidence for,
or against, population-based screening for CKD. The focus will be on the situation of
screening asymptomatic individuals at early stages of CKD regardless of the presence
or absence of CKD risk factors.
Challenges in measuring renal function
Kidney function is usually measured by estimating glomerular filtration rate (GFR),
which is currently considered to be the best index. A direct measurement of GFR is
possible, such as by assessing urinary iothalamate or inulin clearance, but this is cum-
bersome and not suitable for route clinical or population screening. Several equations
have been proposed to estimate GFR (eGFR) from serum creatinine and the currently
recommended equation for adults is the Chronic Kidney Disease-Epidemiology Collab-
oration (CKD-EPI) equation [6]. The CKD-EPI equation also takes age, sex and race
into account, because of their association with muscle mass, which influences the gen-
eration of creatinine. It is particularly challenging to accurately estimate eGFR in older
adults, because the increase in serum creatinine reflecting reduced kidney function is
paralleled by an age-related decrease in muscle mass [7]. Another issue is the need to
calibrate serum creatinine assays across laboratories to use them to estimate GFR [8, 9].
Because creatinine depends on muscle mass and other factors, such as diet, that influence
creatinine generation, there have been efforts to identify a marker of glomerular filtration
that does not suffer from these limitations. Cystatin C, an endogenous protein produced
by nearly all human cells that is freely filtered by the glomeruli, has recently been pro-
posed as a new marker. Cystatin C-based equations to estimate GFR are now available
[10–14]. Compared to creatinine, cystatin C-based equations better predicted all-cause
mortality and cardiovascular events in people older than 65 years [15] as well as all-cause
mortality and end-stage renal disease (ESRD) in general adult populations [11]. Cystatin C
may be combined with creatinine to estimate GFR [11], as demonstrated by some recently
published equations cited above [13, 14]. Markers of glomerular filtration (e.g. serum cre-
atinine and cystatin C) and markers of kidney damage (e.g. albuminuria, renal biopsy find-
ings) are also part of the tests used to define CKD-staging.
How to diagnose chronic kidney disease?
CKD is defined by the Kidney Disease: Improving Global Outcomes Initiative (KDOQI)
as abnormalities of kidney structure or function, present for more than 3 months, with
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implications for health [16]. The following criteria are considered as markers of kidney
damage: albuminuria (albumin excretion rate of 30 mg/24 h or higher or albumin-
creatinine ratio ≥ 30 mg/g); abnormal urine sediment; abnormal histology; structural
abnormalities detected at imaging; history of kidney transplantation or present of kid-
ney damage; eGFR < 60 mL/min/1.73 m2 for ≥3 months). KDIGO revised CKD staging
by categorizing GFR into 6 stages and albuminuria into 3 stages (Table 1). In its early
stages, CKD is almost always asymptomatic, which makes early CKD diagnosis of inter-
est for population screening.
Chronic kidney disease burden
CKD is associated with an elevated risk of all-cause mortality, the lower the kidney
function, the higher the risk [17–19]. Albuminuria provides prognostic information
with respect to all-cause and cardiovascular mortality as well as acute kidney injury,
progression of CKD and ESRD, independently of estimated glomerular filtration rate
(eGFR) [20, 21]. Compared to a person with an eGFR > 60 mL/min/1.73 m2, a person
with an eGFR between 45 and 59 mL/min/1.73 m2 has 20 % higher mortality, a person
with an eGFR between 30 to 44 mL/min/1.73 m2 has 80 % higher mortality, and a per-
son with an eGFR below 30 has mL/min/1.73 m2 more than three-fold higher all-cause
mortality [17]. The associated risks of cardiovascular events, and of hospitalizations,
are of similar magnitudes than those observed for all-cause mortality at each of these
eGFR categories, independently of diabetes, hypertension, dyslipidemia and prior car-
diovascular disease (CVD) [17, 19]. The latest large-scale meta-analysis of cohorts
highlighted a j-shaped relationship between eGFR and all-cause and cardiovascular
mortality with the lowest mortality observed at an eGFR of about 95 mL/min/1.73 m2
[20]. The higher mortality observed in people with high eGFR may potentially reflect
the deleterious effects of glomerular hyperfiltration or be the consequence of low
creatinine generation in people with muscle wasting (e.g. cancer). In people with hyper-
tension, diabetes or CVD, both low eGFR and the presence of albuminuria are inde-
pendently associated with all-cause and cardiovascular mortality [22]. Also, there is no
evidence that diabetes modifies the mortality risk associated with reduced eGFR or the
presence of albuminuria [23].
Natural history of renal function
The major risk factors for CKD include older age, diabetes, arterial hypertension, car-
diovascular disease (CVD), obesity and selected ethnic groups [24–28]. Renal function
Table 1 Chronic kidney disease by GFR and albuminuria stages (adapted from [16] and [61])
Albuminuria stages (mg/g)
A1: < 30 A2: 30–299 A3: >300
GFR stages (mL/min/1.73 m2) G1 ≥90 No CKD CKD G1-A2 CKD G1-A2
G2 60-89 No CKD CKD G2-A2 CKD G2-A3
G3a 45-59 CKD G3a-A1 CKD G3a-A2 CKD G3a-A3
G3b 30-44 CKD G3b-A1 CKD G3b-A2 CKD G3b-A3
G4 15-29 CKD G4a-A1 CKD G4a-A2 CKD G4a-A3
G5 <15 CKD G5a-A1 CKD G5a-A2 CKD G5a-A3
GFR glomerular filtration rate, CKD chronic kidney disease
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gradually decreases with age [29, 30]. Yet, there is large inter-individual variability in
age-related kidney function decline [7, 28, 31–33], with some people being rapid pro-
gressors and others non-progressors. So far, our ability to predict rapid progression has
been limited [34]. In longitudinal studies, the average rate of eGFR decline varied from
0.4 to 1.2 mL/min/1.73 m2/year in healthy adults, was usually higher in patients with
comorbidities or in older people (i.e. 1 to 2 mL/min/1.73 m2/year) and even higher in
patients with CKD (i.e. 2 to 5 mL/min/1.73 m2/year) [30]. People with rapid age-related
eGFR decline have higher all-cause and cardiovascular mortality, independently of
baseline eGFR level [7, 28, 31, 35], which underscores the importance of taking not
only point-estimates of kidney function into account, but also longitudinal variation.
Rapid eGFR decline was also associated with higher incidence of cardiovascular events
[33]. There is however some uncertainty regarding how to best define rapid eGFR de-
cline [30]. Some studies have used absolute [7, 32, 33] and others relative (i.e. percent
changes) [16, 31, 35] eGFR differences. Of interest, people with CKD stage 3, in whom
an increase in eGFR during follow-up is observed, tend to have higher mortality than
those with a stable eGFR with time [31].
Large scale studies found obesity to represent a risk factor for the development of
CKD and ESRD, independently of classical CKD risk factors [36–39], although this in-
dependence is not clear for stage 3 CKD [40]. Obesity also is a risk factor for CKD in
non-diabetic people [41]. The mechanisms by which obesity could negatively influence
renal function are currently unclear [42]. Obesity raises the important issue of whether
or not to index kidney function for body surface area, as is currently the case [43, 44].
Such indexing may lead to underestimate eGFR or, by contrast, may mask obesity-
related glomerular hyperfiltration [43, 44], a potential marker of future kidney function
deterioration.
Although little prospective population-based data are available [30], there is also sub-
stantial intra-individual variability in kidney function trajectory over time, with some
people displaying a linear decline and others a non-linear decline (e.g. eGFR increases
and then rapidly decreases), such as observed in patients with diabetes and/or obesity.
The dynamic variability in eGFR has been inconsistently associated with higher risk of
ESRD [45, 46] and more research is needed in this area, in particular to explore the ef-
fect, and pertinence, of indexing GFR for body surface area.
Principles of population-based screening
The management of screening is a public health service that needs (1) to identify pro-
grammes that do more harm than good at affordable costs and (2) to ensure that the
quality of the programmes are continuously monitored [47].
Elements of a screening programme
“Screening is a programme not a test” [47]. « One of the aims of screening is to control
a disease at the population level ». According to Gray [47], a screening programme is
composed of five basic elements: (1) a target population to be invited at specified inter-
vals; (2) one or more screening tests; (3) one or more diagnostic tests; (4) treatment op-
tions and (5) quality management. A screening programme often has to deal with
opportunistic screening, i.e. screening tests that are made outside of the programme,
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that are often conducted by the private health care sector and are usually not subject to
the same quality controls and evaluation procedures. Depending on the country and
the organization of the health care system, opportunistic screening may create different
problems and consequences.
In 1968, Wilson and Jungner published their seminal report entitled “Principles and
practice of screening for disease” [48]. The idea was to guide the selection of conditions
that would be suitable for screening. Among other criteria, the condition needs to be
detectable at an early stage and be treatable. CKD certainly fulfils these two criteria, in
that kidney function can be easily measured via blood and urine testing (even if one
has to acknowledge the difficulty to precisely and accurately assess GFR in selected
population such as obese, elderly, frail, cachectic or cirrhotic people) and drugs are
available to slow down the decrease in renal function in selected groups. The criteria
proposed by Wilson and Jungner are listed in Table 2, in which a comment was added
to relate them to the specific situation of CKD screening. Additional criteria have since
been added, such as those proposed by the UK National Screening Committee (Table 3).
These new criteria aim to put more emphasis on potential harms of screening pro-
grammes, to clarify the level of evidence needed to consider a programme as efficient
(i.e. high quality randomized controlled trials) and to underline the importance of qual-
ity assurance and programme evaluation [49]. Andermann et al. [50] recently published
revised screening criteria (Table 4).
Table 2 Wilson & Jungner screening criteria in the context of CKD screening (adapted from [48])
Criteria Comment regarding CKD screening
1 The condition is an important health problem. CKD affects one in 10 adults worldwide. CKD
increases the risk of all-cause and CV mortality
and ESRD.
2 There should be an accepted treatment for patients
with recognized disease
Treatment would need to be adapted to the
presence of risk factors and co-morbidities (e.g.
hypertension, diabetes, CVD, etc.)
3 Facilities for diagnosis and treatment should
be available.
Diagnosis and treatment are routinely available in
hospitals and health care centers.
4 There should be a recognizable latent or early
symptomatic stage.
CKD in its early stages (1–3) is almost always
asymptomatic.
5 There should be a suitable test or examination. Serum creatinine, serum cystatin C and urinary
microalbumin represent suitable tests to detect CKD.
6 The test should be acceptable to the population. Serum creatinine, serum cystatin C and urinary
microalbumin are non-invasive and affordable tests.
7 The natural history of the condition, including
development from latent to declared disease,
should be adequately understood.
Several cohort studies have shown a linear
age-related decrease in renal function, but there are
large inter-individual differences. People affected
with CKD either die from CVD or develop ESRD
(dialysis or kidney transplantation).
8 There should be an agreed policy on whom
to treat as patients.
There is high-quality evidence to recommend
treatment with angiotensin II-receptor blockers
in patients with CKD stages 1 to 3 [24], although
evidence is lower in non-diabetic patients [58].
9 The cost of case-finding (including diagnosis
and treatment of patients diagnosed) should be
economically balanced in relation to possible
expenditure on medical care as a whole.
This would need to be determined within each
health care system.
10 Case-finding should be a continuing process
and not a “once and for all” project.
Regular assessments of renal function would be
quite easy to put in place.
CKD chronic kidney disease, CVD cardiovascu lar disease, ESRD end-stage renal disease
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What could be used as a screening test for chronic kidney disease?
A blood test for serum creatinine and a spot urine for albumin-to-creatinine ratio could
represent the first screening tests for CKD. For those testing positive, a confirmation,
i.e. a diagnostic test, should then be done by reassessing eGFR, potentially using both
Table 3 Criteria for appraising the viability, effectiveness and appropriateness of a screening
programme — 2003 (UK National Screening Committee) (authorization obtained from publisher)
1. The condition should be an important health problem.
2. The epidemiology and natural history of the condition, including development from latent to declared
disease, should be adequately understood and there should be a detectable risk factor, disease marker,
latent period or early symptomatic stage.
3. All the cost-effective primary prevention interventions should have been implemented as far as practicable.
4. If the carriers of a mutation are identified as a result of screening the natural history of people with this
status should be understood, including the psychological implications.
5. There should be a simple, safe, precise and validated screening test.
6. The distribution of test values in the target population should be known and a suitable cut-off level defined
and agreed.
7. The test should be acceptable to the population.
8. There should be an agreed policy on the further diagnostic investigation of individuals with a positive test
result and on the choices available to those individuals.
9. If the test is for mutations the criteria used to select the subset of mutations to be covered by screening,
if all possible mutations are not being tested for, should be clearly set out.
10. There should be an effective treatment or intervention for patients identified through early detection,
with evidence of early treatment leading to better outcomes than late treatment.
11. There should be agreed evidence-based policies covering which individuals should be offered treatment
and the appropriate treatment to be offered.
12. Clinical management of the condition and patient outcomes should be optimised in all healthcare
providers prior to participation in a screening programme.
13. There should be evidence from high-quality randomised controlled trials that the screening programme is
effective in reducing mortality or morbidity. Where screening is aimed solely at providing information to
allow the person being screened to make an ‘informed choice’ (for example, Down’s syndrome and cystic
fibrosis carrier screening), there must be evidence from high-quality trials that the test accurately measures
risk. The information that is provided about the test and its outcome must be of value and readily
understood by the individual being screened.
14. There should be evidence that the complete screening programme (test, diagnostic procedures,
treatment/intervention) is clinically, socially, and ethically acceptable to health professionals and the public.
15. The benefit from the screening programme should outweigh the physical and psychological harm
(caused by the test, diagnostic procedures and treatment).
16. The opportunity cost of the screening programme (including testing, diagnosis and treatment,
administration, training and quality assurance) should be economically balanced in relation to
expenditure on medical care as a whole (i.e. value for money).
17. There should be a plan for managing and monitoring the screening programme and an agreed set of
quality assurance standards.
18. Adequate staffing and facilities for testing, diagnosis, treatment, and programme management should
be available prior to the commencement of the screening programme.
19. All other options for managing the condition should have been considered (for example, improving
treatment and providing other services), to ensure that no more cost-effective intervention could be
introduced or current interventions increased within the resources available.
20. Evidence-based information, explaining the consequences of testing, investigation, and treatment,
should be made available to potential participants to assist them in making an informed choice.
21. Public pressure for widening the eligibility criteria for reducing the screening interval, and for increasing
the sensitivity of the testing process, should be anticipated. Decisions about these parameters should be
scientifically justifiable to the public.
22. If screening is for a mutation, the programme should be acceptable to people identified as carriers and
to other family members.
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serum creatinine and cystatin C, and urine analysis at three months, and likely adding
a non-invasive imaging of the kidneys. Cost considerations and analytic validity of the
tests need to be carefully considered when deciding on which tests to use within a
given context. In particular, the measurement of cystatin C currently has a much higher
cost (about 10 times higher) than that of creatinine.
Population-based versus opportunistic screening
Population-based screening programmes target groups of people and not individuals. As
such, they can be contrasted with opportunistic screening that individuals seek from their
medical doctor, outside of a formal population screening programme. When making the
decision to start or not a screening programme, policy makers always consider cost issues,
the idea being to maximize the value obtainable from the available resources [51]. Health
authorities have to consider not only the evidence and needs of the population but also
the values of that population [51]. It may therefore well be that a specific programme is
adapted to the values of one population but not to those of another population, even if
the programme is evidence-based. Economists, epidemiologists, and public health profes-
sionals gather evidence about a programme, yet values have to be decided by the public,
or usually, by their elected representatives [51].
CKD screening recommendations
Current guidelines of the American College of Physicians [24] recommend against
screening for CKD in asymptomatic adults without risk factors for CKD. There is only
Table 4 Emerging screening criteria proposed over the past 40 years in the context of CKD
screening (adapted from Andermann et al. [50])
Criteria Comment regarding CKD screening
1 The screening programme should respond to
a recognized need.
The current situation of population ageing with
increasing incidence of CKD and ESRD and their
associated costs strongly suggest that there is a need.
2 The objectives of screening should be defined
at the outset.
The objective should be to decrease all-cause and
CV mortality as well as ESRD incidence and mortality
and also to improve the quality of life of people
living with CKD.
3 There should be a defined target population. Although no consensus exists for CKD screening,
the sharp age-related increase in CKD prevalence
suggests starting screening after the age of 50 years.
4 There should be scientific evidence of screening
programme effectiveness.
No such evidence currently exists.
5 The programme should integrate education,
testing, clinical services and programme management.
No programme is currently being tested.
6 There should be quality assurance, with mechanisms
to minimize potential risks of screening.
No programme is currently being tested.
7 The programme should ensure informed choice,
confidentiality and respect for autonomy.
No programme is currently being tested.
8 The programme should promote equity and access
to screening for the entire target population.
No programme is currently being tested.
9 Programme evaluation should be planned from
the outset.
No programme is currently being tested.
10 The overall benefits of screening should outweigh
the harm.
No such evidence currently exists.
CKD chronic kidney disease, CVD cardiovascular disease, ESRD end-stage renal disease
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low-quality evidence available so that this recommendation is of weak grade. The UK
National Screening Committee does not recommend population screening for kidney
disease in general (http://legacy.screening.nhs.uk/kidneydisease). The US Preventive
Services Task Force (USPSTF, www.uspreventiveservicestaskforce.org) considers that
there is insufficient evidence to assess the benefits and harms of screening for CKD in
asymptomatic individuals in the absence of diabetes or hypertension. No population-
based study explored the sensitivity and specificity of screening for CKD using eGFR or
albuminuria or both, neither once nor multiple times [24, 52]. So far there are no con-
trolled clinical trials comparing outcomes with and without CKD screening in the
population [52].
What criteria should be met for population-based screening to be
recommended?
In the absence of evidence, such as is currently the case, population-based screening for
CKD cannot be recommended [53]. Given the high burden associated with CKD and its
complications, it would seem appropriate to initiate a randomized controlled trial for
CKD screening in the general adult population. The project should explore which screen-
ing modality would carry the optimal sensitivity and specificity in the context of CKD
screening: creatinine-based eGFR alone? albumin-to-creatinine ratio in spot urine? both
tests? single versus multiple tests? Furthermore the best age range to define the target
population would need to be determined. Considering the age-dependent prevalence, it is
likely that CKD screening would not be very efficient before the age of 50 years. The opti-
mal screening interval should also be explored (yearly? every 2 years? etc.). The current
KDIGO definition does not factor age into the CKD staging system, which has been re-
peatedly criticized [54] and debated [55]. A detailed discussion about the need for revised
criteria for CKD-staging is beyond the scope of this review, but this clearly represents an
important question when choosing a proper CKD screening test.
There is good evidence that early lifestyle and pharmacologic interventions can slow
down CKD progression and reduce CV risk [56]. There is no uniform treatment option
for patients with CKD as the treatment strategy strongly depends on the presence of
comorbidities, such as diabetes, dyslipidemia, hypertension and on overall cardiovascu-
lar risk [21]. In diabetic patients, ACE inhibitor treatment reduces the doubling of
serum creatinine level by 42 % (OR[95 % CI]: 0.58 [0.32–0.90]) [57]. There is a lack of
trials evaluating CKD treatment in non-diabetic and non-hypertensive individuals.
Blood pressure should be adequately controlled in patients with CKD, with tighter
control in the presence of albuminuria [21]. There is high-quality evidence to recom-
mend treatment with angiotensin II-receptor blockers in patients with CKD stages 1 to
3 [24], although evidence is lower in non-diabetic patients [58]. Diabetes, if present,
should be adequately controlled [21]. Current KDIGO guidelines recommend lipid low-
ering treatment in patients with stage 1–5 CKD aged older than 50 years [59]. For
CKD patients younger than 50 years, lipid lowering treatment is recommended in case
of diabetes, known vascular disease or whenever CV risk is higher than 10 % [59]. Life-
style modifications expected to slow down CKD progression include low dietary salt
and protein intake, regular physical exercise, weight maintenance and smoking cessa-
tion [21]. Another important issue in patients with CKD is that of adapting dosage for
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drugs cleared by the kidney. Detailed guidelines regarding drug dosage adjustment in
patients with CKD have been published [60].
Potential harms of screening
As highlighted by Gray [47], screening programmes generate specific harms that dif-
fer from those encountered in clinical care. In usual clinical care, a person seeks the
help of a professional because of a specific problem. After having received adequate
information, this person accepts the risk that the treatment might involve. In a
screening programme, some people (false positive screening tests) may suffer from
adverse effects of screening (e.g. colon perforation following a colonoscopy) without
having the condition (e.g. colon cancer) for which they have been screened [47]. It is
therefore of paramount importance that screening programmes gather evidence about
the harm they may generate [47]. For the situation of CKD screening, the screening
and diagnostic tests (blood and urine sampling) do not generate life-threatening com-
plications, although the psychological harm of being labeled as suffering from CKD
cannot be excluded. Screening and monitoring harms are poorly described for CKD
so far [52].
Conclusions
CKD in its early stages is asymptomatic. CKD affects one in ten adult in the general
population and its prevalence sharply increases with age. CKD is associated with high
cardiovascular morbidity and mortality and high risk of ESRD. In the absence of
evidence for benefit, most public health authorities currently recommend against
population-based screening for CKD. Considering the weakness of the available evi-
dence, the increasing public health burden of CKD and the current context of popula-
tion ageing, it seems appropriate and timely to initiate randomized clinical trials
comparing outcomes with and without CKD screening in the general adult population.
Such trials are needed to explore whether benefits, if any, outweigh harms. If net bene-
fits are demonstrated at the population level, cost issues need to be explored but these
considerations will strongly depend on the resources available in any specific country
or region.
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